Biggest changeThe following table discloses the breakdown of general and administrative expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2023 2022 Payroll and related expenses 1,815 1,845 Share-based payment 212 323 Professional services 1,635 1,451 Travel expenses 61 115 Rent and office maintenance 139 118 Depreciation 20 20 Marketing and other 457 393 Total 4,339 4,265 45 Comparison of the Year Ended December 31, 2023, to the Year Ended December 31, 2022 Results of Operations December 31 December 31, (in thousands of USD) 2023 2022 Revenues 142 421 Cost of revenues (61 ) (661 ) Gross profit 81 (240 ) Research and development expenses (7,145 ) (6,230 ) General and administrative expenses (4,339 ) (4,265 ) Operating loss (11,403 ) (10,735 ) Financial income, net 255 260 Net Loss (11,148 ) (10,475 ) Revenues Our revenues for the year ended December 31, 2023, amounted to $142,000 representing a decrease of $279,000 or 66% compared to $421,000 for the year ended December 31, 2022.
Biggest changeThe following table discloses the breakdown of general and administrative expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2024 2023 Payroll and related expenses 1,733 1,815 Share-based payment 126 212 Professional services 1,593 1,635 Travel expenses 84 61 Rent and office maintenance 138 139 Depreciation 13 20 Marketing and other 488 457 Total 4,175 4,339 Comparison of the Year Ended December 31, 2024, to the Year Ended December 31, 2023 Results of Operations December 31 December 31, (in thousands of USD) 2024 2023 Revenues 1,300 142 Cost of revenues (850 ) (61 ) Gross profit 450 81 Research and development expenses (5,279 ) (7,145 ) General and administrative expenses (4,175 ) (4,339 ) Operating loss (9,004 ) (11,403 ) Financial (expenses) income: Revaluation of derivatives and warrants liabilities (20,181 ) - Other financing income (expenses), net (1,523 ) 255 Net Loss (30,708 ) (11,148 ) Revenues Our revenues for the year ended December 31, 2024, amounted to $1,300,000 representing an increase of $1,158,000 or 815% compared to $142,000 for the year ended December 31, 2023.
Financing Activities Net cash provided by financing activities in the year ended December 31, 2023, consisted of $5,397,000 in proceeds from the issuance of ordinary shares and warrants, net of issuance expenses, from a series of transactions we executed in May 2023 as detailed below.
Net cash provided by financing activities in the year ended December 31, 2023, consisted of $5,397,000 in proceeds from the issuance of ordinary shares and warrants, net of issuance expenses, from a series of transactions we executed in May 2023 as detailed below.
In addition, we believe that our technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality. 44 A. Operating Results Operating Expenses Our current operating expenses consist of two components — research and development expenses, and general and administrative expenses. To date, we have not generated significant revenues.
In addition, we believe that our technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality. A. Operating Results Operating Expenses Our current operating expenses consist of two components — research and development expenses, and general and administrative expenses. To date, we have not generated significant revenues.
Operating and Financial Review and Prospectus—Operating Results” and elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2023 to December 31, 2023 that are reasonably likely to have a material effect on our total revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition.
Operating and Financial Review and Prospectus—Operating Results” and elsewhere in this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2024 to December 31, 2024 that are reasonably likely to have a material effect on our total revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition.
Operating Results— Comparison of the year ended December 31, 2023 to the year ended December 31, 2022— Research and Development Expenses.” 50 D. Trend Information Other than as disclosed in “Item 5.
Operating Results— Comparison of the year ended December 31, 2024 to the year ended December 31, 2023— Research and Development Expenses.” D. Trend Information Other than as disclosed in “Item 5.
The following discussion of the financial condition and results of operations is for the years ended December 31, 2023 and 2022.
The following discussion of the financial condition and results of operations is for the years ended December 31, 2024 and 2023.
Until we close one or more equity financing transactions in an aggregate amount of at least $5 million (including the conversion of the Credit Facility), we had the right to convert into ordinary share up to $1.5 million, including accrued interest, of a loan extended or to be extended to us by the Lender, or the January 2024 Conversion Loan Amount, in connection with and in the framework of a financing transaction of ours on the date that follows the date upon which we notified the Lender of such financing transaction, which conversion will occur upon the same terms.
As a result, the Lender’s financing obligations have terminated pursuant to the terms of the Facility Agreement. 54 Until we close one or more equity financing transactions in an aggregate amount of at least $5 million (including the conversion of the Credit Facility), we had the right to convert into ordinary share up to $1.5 million, including accrued interest, of a loan extended or to be extended to us by the Lender, or the January 2024 Conversion Loan Amount, in connection with and in the framework of a financing transaction of ours on the date that follows the date upon which we notified the Lender of such financing transaction, which conversion will occur upon the same terms.
In a concurrent private placement, or the Private Placement, we also agreed to issue to the same investors a total of warrants to purchase an aggregate of 493,424 ordinary shares, or the Concurrent Warrants, at an exercise price of $6.72 per ordinary share.
In a concurrent private placement, or the Private Placement, we also agreed to issue to the same investors a total of warrants to purchase an aggregate of 493,424 ordinary shares, or the Concurrent Warrants, at an exercise price of $6.72 per ordinary share. The transactions closed on May 11, 2023.
E. Critical Accounting Estimates We describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2023. We believe that the accounting policies below are critical in order to fully understand and evaluate our financial condition and results of operations.
E. Critical Accounting Estimates We describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2024. We believe that the accounting policies below are critical in order to fully understand and evaluate our financial condition and results of operations. We prepare our financial statements in accordance with U.S. GAAP.
The remaining amount of $3,087,000 was used, for professional services, travel, rent and other miscellaneous expenses. Investing Activities Net cash used in investing activities of $152,000 during 2023 and $29,000 during 2022, primarily reflected the purchase of fixed assets in both periods.
The remaining amount of approximately $3,032,000 was used for professional services, marketing, travel, rent and other miscellaneous expenses. Investing Activities Net cash used in investing activities of $30,000 during 2024 and $152,000 during 2023, primarily reflected the purchase of fixed assets in both periods.
Contractual Obligations The following table summarizes our contractual obligations at December 31, 2023: Total Less than 1 year 1-3 years 3-5 years More than 5 years (in thousands of U.S. dollars) Operating leases $ 849 $ 313 $ 536 $ - $ -- C. Research and development, patents and licenses, etc.
Contractual Obligations The following table summarizes our contractual obligations at December 31, 2024: Total Less than 1 year 1-3 years 3-5 years More than 5 years (in thousands of U.S. dollars) Operating leases $ 541 $ 320 $ 221 $ - $ — 56 C. Research and development, patents and licenses, etc.
Since inception, we have not generated significant revenues from the sale of products, and we do not expect to generate significant revenues from the sale of our products in the near future. 49 As of December 31, 2023, our cash and cash equivalents were $3.1 million.
Since inception, we have not generated significant revenues from the sale of products, and we do not expect to generate significant revenues from the sale of our products in the near future. 55 As of December 31, 2024, our cash and cash equivalents were $17.2 million.
Liquidity and Capital Resources Overview Since our inception through December 31, 2023, we have funded our operations principally with approximately $68.7 (net of issuance expenses) from the issuance of ordinary shares, preferred shares, and warrants in public and private offerings. As of December 31, 2023, we had approximately $3.1 in cash and cash equivalents.
Liquidity and Capital Resources Overview Since our inception through December 31, 2024, we have funded our operations principally with approximately $86 million (net of issuance expenses) from the issuance of ordinary shares, preferred shares, and warrants in public and private offerings. As of December 31, 2024, we had approximately $17.5 in cash and cash equivalents.
Net Loss As a result of the foregoing, our net loss for the year ended December 31, 2023, was $11,148,000 compared to $10,475,000 for the year ended December 31, 2022, an increase of $673,000 or 6%. 46 B.
Net Loss As a result of the foregoing, our net loss for the year ended December 31, 2024, was $29,000,000 compared to $11,148,000 for the year ended December 31, 2023, an increase of $18,552,000 or 60%. B.
The following table discloses the breakdown of research and development expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2023 2022 Depreciation 151 130 Share-based payment 62 174 Payroll and related expenses 5,671 5,049 Subcontracted work and consulting 4 15 R&D consumables 696 160 Rent and office maintenance 416 355 Travel and other expenses 145 347 Total 7,145 6,230 General and Administrative Expenses General and administrative expenses consist primarily of salaries and related expenses, share-based payment, professional service fees for accounting, legal and bookkeeping, facilities, travel expenses and other general and administrative expenses.
Research and Development Expenses, net Our research and development expenses consist primarily of salaries and related personnel expenses (including share-based payment), subcontractor’s expenses and other related research and development expenses. 50 The following table discloses the breakdown of research and development expenses: Year ended December 31, Year ended December 31, (in thousands of USD) 2024 2023 Depreciation 134 151 Share-based payment 120 61 Payroll and related expenses 4,216 5,671 Subcontracted work and consulting - 5 R&D consumables 291 696 Rent and office maintenance 413 416 Travel and other expenses 105 145 Total 5,279 7,145 General and Administrative Expenses General and administrative expenses consist primarily of salaries and related expenses, share-based payment, professional service fees for accounting, legal and bookkeeping, facilities, travel expenses and other general and administrative expenses.
The remaining amount of approximately $2,962,000 was used for professional services, travel, rent and other miscellaneous expenses. Net cash used in operating activities of $9,981,000 during the year ended December 31, 2022, was primarily used for payment of an aggregate of approximately $6,894,000 in salaries and related personnel expenses.
The remaining amount of approximately $3,733 was used for professional services, marketing, travel, rent and other miscellaneous expenses. 52 Net cash used in operating activities of $10,518,000 during the year ended December 31, 2023, was primarily used for payment of an aggregate of approximately $7,486,000 in salaries and related personnel expenses.
The table below presents our cash flows for the periods indicated: December 31, December 31, (in thousands of USD) 2023 2022 Operating activities $ (10,448 ) $ (9,981 ) Investing activities $ (152 ) $ (29 ) Financing activities $ 5,397 $ 16,653 Net increase (increase) in cash and cash equivalents $ (5,203 ) $ 6,643 Operating Activities Net cash used in operating activities of $10,448,000 during the year ended December 31, 2023, was primarily used for payment of an aggregate of approximately $7,487,000 in salaries and related personnel expenses.
The table below presents our cash flows for the periods indicated: December 31, December 31, (in thousands of USD) 2024 2023 Operating activities $ (9,682 ) $ (10,518 ) Investing activities $ (30 ) $ (152 ) Financing activities $ 23,918 $ 5,397 Effect of exchange rate changes on cash and cash equivalents (27 ) 70 Net increase (decrease) in cash and cash equivalents $ 14,179 $ (5,203 ) Operating Activities Net cash used in operating activities of $9,682,000 during the year ended December 31, 2024, was primarily used for payment of an aggregate of approximately $5,949,000 in salaries and related personnel expenses.
General and administrative expenses Our general and administrative expenses totaled $4,339,000 for the year ended December 31, 2023, representing an increase of $74,000 or 2% compared to $4,265,000 for the year ended December 31, 2022.
General and administrative expenses Our general and administrative expenses totaled $4,175,000 for the year ended December 31, 2024, representing a decrease of $164,000 or 3.8% compared to $4,339,000 for the year ended December 31, 2023.
Discussion regarding our financial condition and results of operations for the year ended December 31, 2022 as compared to the year ended December 31, 2021 is included in Item 5 of our Annual Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 23, 2023.
Discussion regarding our financial condition and results of operations for the year ended December 31, 2023 as compared to the year ended December 31, 2022 is included in Item 5 of our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on March 28, 2024. 49 Overview We are an early commercialization stage technology company that is seeking to revolutionize railway safety and the data-related market.
The January 2024 PIPE Ordinary Share Warrants are exercisable upon issuance at an exercise price of $0.98475 per ordinary share, subject to certain adjustments and certain anti-dilution protection set forth therein, and have a 5.5-year term from the issuance date. 47 In connection with the closing of the January 2024 PIPE, we exercised our conversion right, or the Conversion Right, pursuant to the Facility Agreement (as defined below) to convert $500,000 of the Credit Facility (as defined below) as a portion of the January 2024 Conversion Loan Amount (as defined below).
The January 2024 PIPE Ordinary Share Warrants are exercisable upon issuance at an exercise price of $0.98475 per ordinary share, subject to certain adjustments and certain anti-dilution protection set forth therein, and have a 5.5-year term from the issuance date.
As of the date of this Annual Report, 1,394,999 January 2024 PIPE Pre-Funded Warrants, 507,743 Facility Conversion Pre-Funded Warrant, 761,615 Facility Conversion Common Warrant and 4,269,688 January 2024 PIPE Warrants have been exercised resulting in gross proceeds of approximately $5.0 million to the Company Execution of Credit Facility Agreement and Issuance of Warrant (January 2024) On January 9, 2024, we entered into a facility agreement, or the Facility Agreement, for a $6 million credit facility, or the Credit Facility, and an additional amount up to $3 million, subject to certain conditions, or the Additional Loans, with a global investment firm, or the Lender, who was also an Investor in the January 2024 PIPE.
Execution of Credit Facility Agreement and Issuance of Warrant (January 2024) On January 9, 2024, we entered into a facility agreement, or the Facility Agreement, for a $6 million credit facility, or the Credit Facility, and an additional amount up to $3 million, subject to certain conditions, or the Additional Loans, with a global investment firm, or the Lender, who was also an Investor in the January 2024 PIPE.
Research and Development Expenses Our research and development expenses for the year ended December 31, 2023, amounted to $7,145,000 representing an increase of $915,000 or 15% as compared to $6,230,000 for the year ended December 31, 2022.
Research and Development Expenses Our research and development expenses for the year ended December 31, 2024, amounted to $5,279,000 representing a decrease of $1,866,00 or 26.1 % as compared to $7,145,000 for the year ended December 31, 2023.
Without derogating from the foregoing estimate regarding our existing capital resources and cash flows from operations, we may decide to raise additional funds in 2024. We believe that, if required, we will be able to raise additional capital or reduce discretionary spending to provide the required liquidity beyond the next twelve months.
We believe that, if required, we will be able to raise additional capital or reduce discretionary spending to provide the required liquidity beyond the next twelve months.
As of the date of this Annual Report, 920,000 January 2024 Facility Warrants have been exercised resulting in gross proceeds of approximately $0.375 million to the Company.
As of the date of this Annual Report, 17,170,000 January 2024 Facility Warrants have been exercised resulting in gross proceeds of approximately $7.0 million to the Company. See “Item 7.B.—Major Shareholders and Related Party Transactions—Related Party Transactions—Pure Capital—Execution of Credit Facility Agreement and Issuance of Warrant (January 2024)” for additional information.
As a result of the cashless exercise, we issued 181,002 ordinary shares to such investors.
Cashless Exercise of Warrants (January 2024) In January 2024, investors from our Private Placement (as defined below) from May 2023 exercised 493,424 Concurrent Warrants on a cashless basis. As a result of the cashless exercise, we issued 181,002 ordinary shares to such investors.
The KB Warrants are exercisable at $6.72 per ordinary share. The KB Private Placement closed on June 21, 2023, following approval of such transaction by our shareholders. See “Item 7.B.—Major Shareholders and Related Party Transactions—Related Party Transactions—Knorr-Bremse” for additional information.
The KB Warrants are exercisable at $6.72 per ordinary share. The KB Private Placement closed on June 21, 2023, following approval of such transaction by our shareholders. Current Outlook We have financed our operations to date primarily through proceeds from sales of our equity securities in public and private offerings, as well as a loan from a related party.
The Concurrent Warrants will be exercisable upon issuance and will have a 5-year term from the initial issuance date. The transactions closed on May 11, 2023.
The Concurrent Warrants were exercisable upon issuance and had a 5-year term from the initial issuance date and all of them have been exercised on a cashless basis as detailed above.
In addition, to date, we have received approximately $5.0 million as a result of the exercise of warrants issued in the January 2024 PIPE. We expect that our cash and cash equivalents as of the issuance date of this annual report and the future expected cash flow from sales will be sufficient for 12 months of operations.
We expect that our cash and cash equivalents as of the issuance date of this annual report and the future expected cash flow from sales will be sufficient for at least 27 months of operations. Without derogating from the foregoing estimate regarding our existing capital resources and cash flows from operations, we may decide to raise additional funds in 2025.
The customer is expected to start a long-term pilot soon after completing the installation. In addition, our railway detection system is currently in a pilot phase with several industry leading railway operators as we seek to move to the next stage of receiving commercial orders.
We are currently engaged on a number of projects where we are equipping certain customers with up to 10 systems each and in a pilot phase with several industry leading railway operators as we seek to move to the next stage of receiving commercial roll out orders as we continue our transition of an early commercialization stage company.
Operating loss As a result of the foregoing, our operating loss for the year ended December 31, 2023 was $11,403,000 compared an operating loss of $10,735,000 for the year ended December 31, 2022, an increase of $668,000 or 6%.
This decrease was primarily attributable to a decrease in salaries as part of the process of reducing costs as mentioned above and a decrease in share-based payment expenses of grants which were fully vested or forfeited in 2024. 51 Operating loss As a result of the foregoing, our operating loss for the year ended December 31, 2024, was $9,004,000 compared to an operating loss of $11,403,000 for the year ended December 31, 2023, a decrease of $2,399,000 or 21%.
Overview We are a development stage technology company that is seeking to revolutionize railway safety and the data-related market. We believe we have developed cutting edge, AI based, industry-leading detection technology specifically designed for railways, with investments from Knorr-Bremse, a world-class rail system manufacturer.
We have developed cutting edge, AI based, industry-leading detection technology specifically designed for railways. We have developed our railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operator.